March 01, 2024
GlaxoSmithKline and its attorneys from Shook Hardy & Bacon LLP can recover more than $450,000 in legal costs after beating a multidistrict suit claiming the company's anti-nausea drug Zofran caused birth defects, a federal judge has ruled.
March 16, 2023
Families that sued GlaxoSmithKline claiming its anti-nausea drug Zofran caused birth defects told a federal judge Wednesday that the company can't recoup roughly $578,000 in costs and called it "ironic" and "disheartening" because GSK's firm, Shook Hardy & Bacon LLP, had dropped a similar request in another multidistrict litigation.
June 25, 2021
A U.S. Supreme Court ruling holding that Ford can be held liable for alleged defects in cars originally sold outside a plaintiff's home state and a ruling wiping out hundreds of cases alleging GlaxoSmithKline's anti-nausea drug Zofran causes birth defects are among Law360's top cases for the first six months of 2021.
June 18, 2021
A sweeping order ending more than 400 cases alleging GlaxoSmithKline's anti-nausea medication Zofran causes birth defects provides a "roadmap" for fending off multidistrict litigation with the help of a landmark U.S. Supreme Court ruling, experts say.
June 01, 2021
GlaxoSmithKline will not have to face more than 420 suits in multidistrict litigation alleging its anti-nausea medication Zofran causes birth defects, after a Massachusetts federal judge ruled Tuesday the claims are preempted because federal regulators declined to add a warning label for pregnant women.
April 21, 2021
A federal judge said during a Wednesday hearing that a ruling on whether claims that GlaxoSmithKline's anti-nausea medication Zofran triggers birth defects are preempted will be coming soon, a decision he's called a potential "showstopper" in the multidistrict suit.
March 24, 2021
Lawyers for GlaxoSmithKline argued Wednesday that more than 300 cases in a multidistrict product liability suit over its anti-nausea medication should be nixed since the plaintiffs' own expert determined there is no link between the drug and cardiac birth defects.
February 24, 2021
A Massachusetts federal judge running the first bellwether in multidistrict litigation over whether GlaxoSmithKline's anti-nausea medication Zofran causes birth defects said Wednesday that he's considering an October starting date after a lengthy postponement triggered by the coronavirus pandemic.
November 10, 2020
GlaxoSmithKline on Monday told a Massachusetts federal judge overseeing multidistrict litigation over its anti-nausea medicine Zofran that the U.S. Food and Drug Administration has rejected a proposed label change that would have added birth defect warnings.
June 23, 2020
A Massachusetts federal judge told lawyers representing GlaxoSmithKline and plaintiffs who claim its anti-nausea medicine Zofran caused birth defects that he's open to creative ways to hold a complex jury trial with social distancing, but he may have no choice but to wait until 2021.